3190 results for «779»
3190 results
TEER in complex tricuspid regurgitation - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.
Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.
LIVE Educational Case...
Hot topics and evidence on structural interventions in 2025 and 2026
14 Feb 2026 – From PCR Tokyo Valves 2026
Delve into the emerging clinical evidence and key hot topics shaping transcatheter interventions for aortic, mitral, and tricuspid valve diseases anticipated to influence clinical practice in 2025 and 2026. This session reviews stroke prevention, valve interventions across the three valves, and integrates recent and upcoming data...
Prevention and management of TAVI complications
14 Feb 2026 – From PCR Tokyo Valves 2026
This session addresses the prevention and management of major complications associated with transcatheter aortic valve implantation (TAVI). Attendees will gain a detailed understanding of mechanisms behind cerebral infarction, haemolysis, valve infolding, pacemaker implantation, and valve migration, along with expert strategies for recognition, decision-making, and bailout techniques...
Primary mitral TEER in small anatomy - LIVE case
15 Feb 2026 – From PCR Tokyo Valves 2026
An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).
One Pascal ACE device was implanted.
LIVE Educational Case from Nagoya...
Guidelines update
15 Feb 2026 – From PCR Tokyo Valves 2026
This session reviews the latest updates in the ESC/EACTS guidelines for structural heart disease, emphasizing their clinical implications and future trends. Participants will gain understanding of changes in aortic, mitral, and tricuspid valve recommendations, including new age cutoffs, asymptomatic disease management, and the evolving role of...
Future devices and techniques for structural heart disease
15 Feb 2026 – From PCR Tokyo Valves 2026
This session surveys the future landscape of structural heart disease treatment, addressing current limitations in transcatheter valve technologies and presenting emerging devices and techniques for aortic, mitral, and tricuspid valves. Attendees will gain insights into innovations poised to transform therapeutic options for structural heart disease.
MATTERHORN - Transcatheter versus surgical mitral valve repair in patients with heart failure and secondary mitral regurgitation
01 Sep 2024
Yohei Ohno provides his takeaways from the results of the MATTERHORN trial presented by Volker Rudolph at the ESC Congress 2024 in London.
Author
REC-CAGEFREE I - Drug-coated balloon angioplasty with rescue stenting versus intended stenting for the treatment of de novo coronary artery lesions
08 Sep 2024
Mirvat Alasnag provides her take on REC-CAGEFREE I, a multicenter, non-inferiority trial presented at the ESC Congress 2024 in London.
Author
One-year results of the Clasp TR Study: Transcatheter treatment of tricuspid regurgitation
22 Mar 2022
Alessandro Sticchi and Luigi Biasco provide their take on the 1-year results of the CLASP TR study which were presented by Dr Adan Greenbaum, co-director of the Emory Structural Heart and Valve Center (Atlanta, GA) during the 2022 American College of Cardiology annual Congress held in Washington D.C.
Author
Author
Angiography-derived fractional flow reserve versus intravascular ultrasound to guide percutaneous coronary intervention in patients with coronary artery disease: the FLAVOUR II trial
29 Mar 2025
Ali Nazmi Calik provides his take on the FLAVOUR II trial presented by Jian-An Wang at ACC.25 in Chicago.
Author
